The potential to backfill in phase I trials: the National Cancer Institute’s Cancer Therapy Evaluation Program experience
JNCI Cancer Spectrum · 2023
DOI: 10.1093/jncics/pkad102 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift JNCI Cancer Spectrum, 2023. Verfasst von Jared C Foster und 3 weiteren Autor:innen. Beteiligte Einrichtung: Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USA. Hauptthemen laut MEDLINE: Research Design, Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 7 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Jared C Foster, PhD, Edward L Korn, PhD, Boris Freidlin, PhD, Jeffrey A Moscow, MD; The Potential to Backfill in Phase I Trials: the CTEP/NCI Experience, JNCI C
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USA.
- Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USA.
ORCID-Profile: Jared C Foster, Boris Freidlin
Zitieren
APA
Foster, J. C., Korn, E. L., Freidlin, B., & Moscow, J. A. (2023). The potential to backfill in phase I trials: the National Cancer Institute’s Cancer Therapy Evaluation Program experience. JNCI Cancer Spectrum. https://doi.org/10.1093/jncics/pkad102
Vancouver
Foster JC, Korn EL, Freidlin B, Moscow JA. The potential to backfill in phase I trials: the National Cancer Institute’s Cancer Therapy Evaluation Program experience. JNCI Cancer Spectrum. 2023. doi:10.1093/jncics/pkad102
BibTeX
@article{Foster2023,
author = {Foster, Jared C and Korn, Edward L and Freidlin, Boris and Moscow, Jeffrey A},
title = {The potential to backfill in phase I trials: the National Cancer Institute’s Cancer Therapy Evaluation Program experience},
journal = {JNCI Cancer Spectrum},
year = {2023},
doi = {10.1093/jncics/pkad102}
}
EUVIMED